Nevertheless, the demonstration of anti-tumor efficacy in a tolerized animal model provided the rationale for future Lm-based immunotherapies to target self-TAAs such as Her2/neu and VEGFR-2 (Singh et al., 2005; Singh and Paterson, 2006a,b, 2007a,b; Seavey et al., 2009b). Here, ERBB2 is linked to neoplasm.